OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis $28.90 -0.67 (-2.27%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Daiichi Sankyo Stock (OTCMKTS:DSNKY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daiichi Sankyo alerts:Sign Up Key Stats Today's Range$28.76▼$29.0050-Day Range$28.90▼$36.4052-Week Range$26.16▼$42.48Volume99,715 shsAverage Volume114,719 shsMarket CapitalizationN/AP/E Ratio0.25Dividend Yield77.75%Price TargetN/AConsensus RatingN/A Company OverviewDaiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Daiichi Sankyo Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks16th Percentile Overall ScoreDSNKY MarketRank™: Daiichi Sankyo scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Daiichi Sankyo. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Daiichi Sankyo is 0.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Daiichi Sankyo is 0.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.86. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently increased by 4,266.67%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDaiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDaiichi Sankyo does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Daiichi Sankyo's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently increased by 4,266.67%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentDaiichi Sankyo has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Daiichi Sankyo this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Daiichi Sankyo is held by institutions.Read more about Daiichi Sankyo's insider trading history. Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Stock News HeadlinesDaiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third timeNovember 20 at 2:56 PM | msn.comDaiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy RatingNovember 13, 2024 | markets.businessinsider.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 21, 2024 | DTI (Ad)Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOSNovember 13, 2024 | finance.yahoo.comAstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecanNovember 12, 2024 | markets.businessinsider.comAlteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ TechnologyNovember 10, 2024 | finance.yahoo.comAlteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU DevelopmentNovember 10, 2024 | markets.businessinsider.comENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology ProductNovember 8, 2024 | finance.yahoo.comSee More Headlines DSNKY Stock Analysis - Frequently Asked Questions How have DSNKY shares performed this year? Daiichi Sankyo's stock was trading at $27.35 on January 1st, 2024. Since then, DSNKY shares have increased by 5.7% and is now trading at $28.90. View the best growth stocks for 2024 here. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:DSNKY CUSIPN/A CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.25 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:DSNKY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.